Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions

Description

Heart failure is a syndrome that is defined by distinctive clinical, hemodynamic, and neurohormonal findings. HF represents a final common pathway for many different cardiovascular diseases, including coronary disease, hypertension, Valvular disease, and many primary heart muscle diseases. Clinically, HF patients experience dyspnea, fatigue and diminished exercise tolerance, reflecting elevated left and/or right ventricular filling pressures and decreased cardiac output.

Conditions

Heart Failure, ADHF, Acute MI

Talk to us

Study Overview

On this page

Study Details

Study overview

Heart failure is a syndrome that is defined by distinctive clinical, hemodynamic, and neurohormonal findings. HF represents a final common pathway for many different cardiovascular diseases, including coronary disease, hypertension, Valvular disease, and many primary heart muscle diseases. Clinically, HF patients experience dyspnea, fatigue and diminished exercise tolerance, reflecting elevated left and/or right ventricular filling pressures and decreased cardiac output.

Care cOordination Using Mobile Technology to Enhance Patient Empowerment in Acute Comorbidities to aSSess Improvement in Outcomes in Hospital readmissioNs

Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions

Condition
Heart Failure
Intervention / Treatment

-

Contacts and Locations

Phoenix

Multiple Locations, Phoenix, Arizona, United States, 85016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Study informed consent will be obtained before enrollment in the study for Phase 1 and Phase 2
  • 2. All subjects 18 years or above will be a criteria for inclusion for Phase 1
  • 3. For Phase 2, men and women 50 years or older with positive Covid19 antigen test and one other risk factor as mentioned in the comorbid section of workflow will be enrolled in the intervention arm of the study;
  • 4. For phase 2, subjects should be able to be randomized within 48 hours of Covid19 antigen positive status
  • 5. Patients considered unreliable by the investigator concerning the requirements for follow-up visits

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Aventyn, Inc.,

Kris Vijay, MD, STUDY_CHAIR, Abrazo Arizona Heart

Raj Bhat, MD, STUDY_DIRECTOR, Pioneer Hospitalists

Zaki Lababidi, MD, PRINCIPAL_INVESTIGATOR, Gilbert Cardiology

Ashok Solsi, MD, PRINCIPAL_INVESTIGATOR, Premier Cardiovascular Center

Study Record Dates

2026-12-22